
Privacy Policy Legal Notice Cookie Policy
We are a team of multidisciplinary scientists pioneering the discovery and development of novel oral allosteric inhibitors as therapeutic agents to address unmet medical needs in oncology and chronic inflammation.
We design and develop targeted small molecule therapeutic drugs specifically designed to modulate the function of molecular mediators that play a critical role in the onset and progression of chronic inflammation and cancer.
Our trailblazing research has birthed the first-in-class oral inhibitor of IL-1β production, a small molecule that may be a game-changer in the treatment of IL-1β-related diseases that currently lack effective treatment options.
Encompassing a diverse array of cutting-edge small molecule allosteric inhibitors targeting key pathways involved in challenging diseases, our portfolio reflects our dedication to providing impactful and transformative therapies to patients in need.